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ABSTRACT
Objective: The objective of the Predict-HD study is to use
genetic, neurobiological and refined clinical markers to
understand the early progression of Huntington’s disease
(HD), prior to the point of traditional diagnosis, in persons
with a known gene mutation. Here we estimate the
approximate onset and initial course of various measur-
able aspects of HD relative to the time of eventual
diagnosis.
Methods: We studied 438 participants who were
positive for the HD gene mutation, but did not yet meet
the diagnostic criteria for HD and had no functional
decline. Predictability of baseline cognitive, motor,
psychiatric and imaging measures was modelled non-
linearly using estimated time until diagnosis (based on
CAG repeat length and current age) as the predictor.
Results: Estimated time to diagnosis was related to most
clinical and neuroimaging markers. The patterns of
association suggested the commencement of detectable
changes one to two decades prior to the predicted time of
clinical diagnosis. The patterns were highly robust and
consistent, despite the varied types of markers and
diverse measurement methodologies.
Conclusions: These findings from the Predict-HD study
suggest the approximate time scale of measurable
disease development, and suggest candidate disease
markers for use in preventive HD trials.
Huntington’s disease (HD) is a dominantly inher-
ited disease for which predictive testing can inform
whether, but not precisely when, the disorder will
manifest itself. The onset ages for HD have non-
linear inverse relationships with the number of
polyglutamine repeat sequences in the gene muta-
tion so that younger diagnosed patients tend to
have longer repeat lengths.
12Current guidelines for
genetic counselling recommend against using pre-
dictions of diagnosis age, in part because no
curative or preventive treatments are available,
and also because such estimates have large
confidence intervals,
3 making it impossible to
accurately predict when the clinical disease will
become manifest. Nonetheless, DNA based prog-
nostic stratification can play a useful role in
characterising attributes at the group level among
those with various lengths of the HD CAG
expansion. For example, in samples of individuals
with the HD CAG expansion but not yet meeting
diagnostic criteria for HD, at least two studies have
indicated that minor motor signs are evident
several years prior to diagnosis,
45and more than
20 studies have shown measurable cognitive
impairments.
6–11 Psychiatric disturbances are pre-
valent prior to diagnosis of HD.
12–16 At least seven
studies have evaluated volumetric MRI in CAG
expanded individuals prior to diagnosis,
17–21 with a
recent report suggesting that striatal volume loss is
evident at least 9–11 years prior to estimated
onset.
22 Studies using functional MRI have shown
reduced activation patterns in the basal ganglia
23
and cingulate cortex
24 in the absence of volumetric
loss in prediagnosed individuals, suggesting that
abnormalities in cell function may be detectable
prior to cell death. Data from animal studies are
consistent with these findings and indicate that
receptor changes and electrophysiological changes
clearly precede the onset of behavioural pheno-
type(s) in HD transgenic mouse models.
25
Moreover, a few recent longitudinal studies have
validated cross sectional findings of prediagnosis
disease markers.
12 22
To reach the goals of prevention and interven-
tion prior to clinical manifestations of HD, we
must build on this evidence of prediagnostic
changes in the brain and behaviour and attempt
to further infer the longitudinal course of changes
prior to diagnosis. For example, testing of effective
preventive treatments may only be practical once it
is possible to measure early disease progress prior
to manifest clinical debilitation, and then to track
these measures in response to candidate interven-
tions. In this report, we have utilised estimates of
time until diagnosis to examine early declines in
HD biomarker and refined clinical marker changes.
We used a large cohort of prediagnosed partici-
pants from the Predict-HD study, all of whom had
verified and measured CAG expansions for HD.
METHODS
Participants
Predict-HD is a longitudinal study of individuals
known to be at genetic risk for HD. This report is
based on baseline data from all participants
(n=449 with CAG expansions in the HD gene)
who were enrolled from September 2002 until
October 2004. Participants were primarily
Caucasian (96%), right-handed (89%), married
(70%) employed (77%) females (64%) with an
average age of 42.1 (SD 9.9) years. Ninety per cent
had at least a high school education; average years
of education for this sample was 14.5 (SD
2.6) years.
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Canada and three sites in Australia (see Paulsen and colleagues
27
for an overview of recruitment procedures). Study activities
were reviewed and approved by institutional review boards at
all study and data processing sites. Participants underwent
informed consent procedures and signed consents for both
participation and to allow de-identified research data to be sent
to collaborative institutions for analyses.
To ascertain a comparison cohort, sites were asked to enrol a
participant with a CAG repeat length in the reference range (eg,
,30 repeats) for every six participants enrolled with a CAG
repeat length in the HD range (ie, >39 repeats). Inclusion
criteria required participants to have previously undergone
voluntary genetic testing for the presence of the CAG expansion
in the HD gene, huntingtin, on the short arm of chromosome 4.
Exclusion criteria included: (a) clinical evidence of unstable
medical or psychiatric illness; (b) history of other central
nervous system disease or event, such as seizures or head
trauma; (c) pacemaker or metallic implants; and (d) prescribed
antipsychotic or phenothiazine derivative antiemetic medica-
tions within the past 6 months. Other prescribed, over the
counter and natural remedies were not restricted. Although the
intent was to enrol only participants who were prediagnosed,
provisions were made to enrol the few otherwise eligible
individuals who seemed to be having HD symptoms if those
individuals had not been diagnosed as having HD.
Procedure
Participants underwent annual study visits at local sites,
including blood draws, a neurological examination, cognitive
assessment, psychiatric and psychological questionnaires, and
brain MRI. Only a subset of data collected in these assessments
is presented in the current report. Data and samples were sent
from local sites to the Predict specialty sites, including blood
samples to Harvard University for DNA analyses of CAG repeat
lengths, cognitive assessment data to Indiana University at
Bloomington for scoring and quality control, and MRI datasets
to the University of Washington in Seattle for volumetric
analyses of the caudate nucleus and putamen. These data, as
well as general case report forms, were then forwarded to the
Clinical Trials Coordination Center at the University of
Rochester, where data were collated and missing data were
queried. Finally, data sets were sent to the University of Iowa
for construction of the comprehensive database and statistical
analysis.
Data included in the current report
Motor scores
The Unified HD Rating Scale
26 motor examination consists of
15 primary items administered by movement disorder specialists
who had undergone reliability training for the Predict-HD
study. Total motor scores in this sample ranged from 0 to 34
(mean 5.53 (SD 5.40)) of a possible 124 points.
HD diagnostic confidence rating
After performing the motor examination, the movement
disorder specialist assigned a diagnostic opinion, with level of
certainty, according to the following scale: 0=normal (no
abnormalities); 1=non-specific motor abnormalities (less than
50% confidence that the participant has manifest HD);
2=motor abnormalities that may be signs of HD (50–89%
confidence); 3=motor abnormalities that are likely signs of HD
(90–98% confidence); or 4=motor abnormalities that are
unequivocal signs of HD (>99% confidence). This scale is based
on the currently accepted formal diagnostic process, which
requires the emergence of an otherwise unexplained extrapyr-
amidal movement disorder in someone at risk for HD. Thus the
rating does not directly reflect the presence of cognitive or
psychiatric manifestations of HD, which may also be present.
By consensus, a rating of 4 is considered to be the point at
which HD diagnosis is made. As we were focused on HD
development before the point of diagnosis, we excluded 11
participants from this analysis who had a diagnostic rating of 4
on their initial examination. Of the remaining 438 participants
analysed, confidence ratings were as follows: 148 (34%) rated 0,
198 (45%) rated 1, 68 (16%) rated 2 and 24 (5.5%) rated 3.
Determination of CAG length
A previous voluntary decision to undergo HD gene testing was a
prerequisite for entry into the Predict-HD study and clinical
predictive testing results were confirmed by CAG repeat lengths
obtained via PCR, as described elsewhere.
27 For the study
sample, CAG expansions ranged from 39 to 50, with a mean of
42.3 (median 42).
Estimation of time to HD diagnosis
To examine relationships between proximity to HD diagnosis
and motor, brain volumetric and cognitive measures, we used a
CAG based prognostic model developed
3 on the basis of nearly
3000 subjects. This survival formula can be transformed to a
probability distribution for age of diagnosis that depends on
both the subject’s CAG expansion length and current age
(fig 1A). We give details, including assumptions and transfor-
mations to estimate years until diagnosis, in appendix A online.
Briefly, in order to estimate mean time until clinical diagnosis,
we truncate the probability distribution to account for the fact
that a subject has reached their current age without yet
receiving a diagnosis. We then calculate the mean of this revised
distribution (fig 1B). The study sample had a mean estimated
time to diagnosis of 13.9 (SD 6.7) years.
Cognitive assessment
Cognitive testing included nine paper and pencil tests from the
well established clinical neuropsychological literature and nine
computerised tasks developed specifically for Predict-HD which
were administered on standardised specially constructed pc
based computer systems. All study personnel who administered
the cognitive battery underwent in-person training until they
reached the criterion for standardised administration, followed
by annual reliability checks. Only four of 18 tests were used in
the current report. Tests were selected to represent varying
components of brain processes (motor speed, timing, memory
and sensory processes).
Motor speed
The Speeded Tapping Test
28 is a computerised test of finger
tapping speed that requires a participant to press keys on a
response box as quickly as possible. The value analysed for this
study was the average tapping rate. Previous research has
suggested that motor speed may be maintained by the motor/
premotor circuit.
Self-paced timing consistency
Participants tapped on a single key in time to a series of 11
evenly paced tones, after which they had to continue tapping at
the same pace for another 31 taps. To capture the consistency in
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artefact free trials. Previous research indicates that the
dorsolateral circuit may be involved in time discrimination.
Verbal learning/memory (word list learning)
A traditional list learning task, the Hopkins Verbal Learning
Test-Revised,
29 was used. For three trials, participants listened
to the same 12 item word list and had to immediately recall
aloud the words read by the examiner. Human learning and
memory is often associated with frontal temporal circuitry.
Odour recognition
The University of Pennsylvania Smell Identification Test
30 is a
40 item, four choice scratch and sniff test. For the model
analyses, we examined the number of correct identifications out
of a possible 40. Animal and human research suggests that
olfactory performances may be associated with the lateral
orbitofrontal circuit.
MRI measures
All scans for this project were obtained using a standard
protocol designed to optimise visualisation of the basal ganglia.
We obtained an axial three-dimensional volumetric spoiled
gradient echo series, with a flip angle of 20u, TE=3, TR=18,
FOV=24 cm, 124 slices at 1.5 mm/slice, matrix 2566192, L
phase FOV and NEX=2. All sites used a General Electric 1.5 T
scanner (with one exception of a site using a 1.5 T Siemens
scanner). A single rater, who had been trained to .0.95 for
inter-rater reliability with one of the authors (EA), was blinded
to participant characteristics and completed all measurements
for the study. Measurements were made by manually drawing
boundaries of the caudate (head and body) and putamen, as
previously described,
17–21 and total striatal volumes were
calculated based on the number of identified pixels. The data
were analysed in the order received. MRI data from 261 of the
Predict participants had been analysed at the time of this report.
The MRI sample is smaller because of a lag induced by the extra
processing steps needed to produce the volumetric data and does
not reflect any other known sampling bias. Striatal volumes
ranged from 9.2 to 25.4 ml (mean 16.9 (SD 3.0) ml).
Statistical analyses
The primary goal was to use the study’s baseline data to
determine the relationship of estimated years to diagnosis with
biological (brain volume) and refined clinical (cognitive, motor)
measures. Because we wanted to test for non-constant slopes in
these relationships, we fitted flexible non-linear models to
estimate them. Specifically, we fitted least squares models based
on cubic restricted spline transforms of the estimated time to
diagnosis. We used predefined knot locations to improve the
validity of statistical inference.
31 These spline models typically
have an advantage over polynomial models in that, using similar
degrees of freedom to test deviation from strictly straight line
regression, the allowable curvature shapes more plausibly reflect
real physical relationships. To protect against over fitting, we
restricted our choices to splines that added either 1 or 3 extra
degrees of freedom for potential non-linearity and, between
these, selected the model with better adjusted R square
Figure 1 (A) Example estimated probability density function for age at
diagnosis of Huntington’s disease (HD), calculated at birth, for a person
with a CAG expansion length of 42. Line and circle illustrate the expected
age of diagnosis (mean of the distribution), which is 52.2 years.
(B) Example estimated probability density function for age at HD
diagnosis, for a person with a CAG expansion length of 42, given that the
person has reached age 42 years without being diagnosed. Distribution
from (A) is truncated at the present age and the remaining area under the
curve is rescaled to equal 1. Line and circle illustrate the expected age of
diagnosis for this adjusted distribution (ie, the mean of the age
conditional distribution), which is 54.5 years. Therefore, the expected
time until diagnosis is 54.4–42=12.4 years.
Figure 2 Scatterplot of self-timed tapping consistency data and
estimated years from diagnosis of Huntington’s disease (HD). The fitted
spline relationship, including 95% confidence limits for the fit, is
superimposed. The plotted data points are adjusted for age, gender,
education and estimated IQ by linear regression and standardised to a
female with mean values of the other values. As detailed in table 1, the
adjusted per cent variance explained (R
2) for this plot is 0.20.
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participant age, gender and, in the case of cognitive outcomes,
years of education and estimated premorbid IQ (as reflected by
Anart test scores). We made these adjustments by including the
additional terms as conventional multiple regression covariates.
As a secondary analysis, clinical motor score was also controlled
in order to better interpret the results of psychomotor test
analyses.
We performed residual diagnostics on all models. We found
no need to remove more than one outlier in any instance. Such
outliers had small effects on details of the curve fit, but there
was no occasion where they would have changed the statistical
significance of the models.
Spline model results are not readily interpreted in terms of
traditional regression coefficients. Instead, we present graphs of
the fitted curves, along with partial adjusted R square
(‘‘variance explained’’) contributed by the expected time to
diagnosis and the p values for both the total and non-linear
contributions of expected time to diagnosis. Statistical signifi-
cance attached to the non-linear contribution reflects the
Table 1 Non-linear model fits for associations with estimated age at diagnosis
Variable n
Adj
R
2 p Value
Non-linear
df
Non-linear
p value
Motor examination score 438 0.15 ,0.0001 3 ,0.0001
Striatal volume 261 0.23 ,0.0001 1 ,0.001
Speeded finger tapping rate (mean) 408 0.14 ,0.0001 3 ,0.0001
Consistency in self-timed finger tapping 410 0.20 ,0.0001 3 ,0.0001
Word list learning (HVLT) 425 0.09 ,0.0001 1 ,0.01
Odour identification 424 0.10 ,0.0001 1 ,0.0001
Adj R
2=partial adjusted variance accounted for by estimated years to diagnosis to Huntington’s disease (HD) after accounting for
covariates (see statistical methods section) and degrees of freedom used for non-linear fit.
HVLT, Hopkins Verbal Learning Test; Non-linear df, degrees of freedom for non-linear fit; non-linear p value, p value for non-linear
element of estimated years to HD diagnosis fit.
Figure 3 Relationship between
estimated years to diagnosis of
Huntington’s disease (HD) and various
other measures. Solid line plots the
predicted response; broken lines are 95%
confidence limits for the estimated mean
response. All relationships are adjusted to
a female with mean levels of the other
variables for which we adjusted our
models (age=41.2 years,
education=14 years, premorbid IQ).
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changes with estimated time to diagnosis.
RESULTS
A detailed example of one of our analyses is shown in fig 2
where we illustrate the relationship between estimated time to
diagnosis and timing consistency measured by the self-paced
tapping task. The individual data points are included to give a
clear sense of the extent of model fit. In this case, approximately
20% of the subject to subject variability in performance is
explained (table 1). Visually, the non-linear trend captured in
the model is apparent in the raw data. Of course, it is also
evident that there is additional person to person variability that
our model cannot account for.
The estimated relationships between years to diagnosis and
the other outcomes are illustrated in fig 3. As can be seen from
the figures, motor examination scores, odour recognition,
striatal volumes and a wide range of cognitive performances
show a consistent convergent pattern, suggesting that little
impairment is detected prior to 15–20 years from estimated
diagnosis. Then, after a short transition period, a fairly linear
relationship is seen. Table 1 shows model results in terms of
total variance explained by the expected time to diagnosis. In
every instance, both the total relationship with estimated time
until diagnosis and the non-linear component were highly
significant. Variance explained is in the 10–20% range.
It is conceivable that motor deficits may affect performance
on some of the cognitive tests. To determine whether other
associations were redundant with the motor association, we
recomputed the corresponding models after adjusting for motor
score as an additional covariate (see table 2). Although the
association strengths were somewhat weakened, consistent
with partial confounding, the striatal and cognitive variables
still showed substantial non-linear associations.
DISCUSSION
Findings suggest converging evidence from varying markers for
detectable abnormalities beginning between one and two
decades before diagnosis of HD. The relationships between
estimated years to diagnosis and motor scores, striatal volumes,
odour recognition and cognitive measures were strikingly
consistent. On this estimated time scale, all domains suggest a
curvilinear pattern of disease commencement. This period of
commencement is followed by more rapid and constant change
in the last years prior to diagnosis. Our findings are consistent
with previous reports suggesting an association of striatal
volumes with estimated diagnosis based on CAG repeat.
17 18 22
The current sample size is nearly 10 times larger than previous
reports and thus serves both a confirmatory and refining role.
Additionally, demonstration of similar estimated time lines for
cognitive, sensory and motor changes is novel and significantly
extends these findings. We have illustrated a pervasive pattern
of change, occurring on the same time scale, which extends
from biological measures such as striatal volumes to several
different clinical aspects of the HD phenotype.
Our finding that associations between years to diagnosis and
other variables remained, even after controlling for motor signs,
strongly suggests that apparent cognitive and sensory dysfunc-
tion cannot be explained solely on the basis of emerging motor
signs interfering with task performance. It is noteworthy that
these associations remained, regardless of whether the assess-
ment was laden with motor demands (speeded finger tapping,
self-timed finger tapping) or not (verbal learning, odour
identification). The consistency of associations between the
estimated genetic time scale and these diverse cognitive
measures suggests that multiple corticostriatal circuits are
simultaneously involved in early disease, although further
research is needed to more explicitly track the brain behaviour
associations suggested here. Striatal volumes also remained
curvilinearly related to estimated years to diagnosis after
controlling for motor signs. The analyses therefore indicate
that neither cognitive nor striatal measurements are wholly
redundant with the clinical motor examination. It follows that
all of these can likely be combined and leveraged to improve the
accuracy of individualised prognosis. Many of these markers
may be candidate surrogate endpoints (bearing in mind that
promotion from candidate to true surrogate is exceedingly
difficult).
32 However, markers that cannot meet criteria for this
elusive role can still be useful for risk stratification—which is
still quite valuable for increasing clinical trial power in a rare
disease. Quantitative estimation of the impact of these markers
in either role (longitudinal outcome or baseline stratification) is
a substantial topic in its own right. In the near future, we will
address the details of using baseline Predict-HD findings for
increased statistical power and trial design efficiency in a
separate manuscript.
There are some important caveats to consider when inter-
preting these findings. Firstly, the cross sectional associations
require longitudinal validation. With planned follow-up periods
of up to 7 years, the Predict-HD study will eventually yield
appropriate data to attempt this validation. Furthermore, the
study was designed to eventually yield a sufficient sample of
individuals who become diagnosed, allowing CAG based
estimates of average diagnosis age to be validated or refined.
Despite excellent goodness of fit in the original model
derivation,
3 the time scale discussed in the current article
remains provisional until longitudinal study is complete.
Even if the time scale is accurate, estimated time to diagnosis
is clearly an imperfect proxy for actual time to diagnosis, which
is of course unknown in these subjects. Although relationships
Table 2 Non-linear model fits for estimated age at diagnosis associations adjusted for motor scores
Variable n
Adj
R
2 p Value
Non-linear
df
Non-linear
p value
Striatal volume 261 0.20 ,0.0001 1 0.002
Speeded finger tapping rate (mean) 408 0.09 ,0.0001 3 ,0.01
Consistency in self-timed finger tapping 410 0.14 ,0.0001 3 ,0.01
Word list learning (HVLT) 425 0.05 ,0.0001 1 0.10
Odour identification 424 0.07 ,0.0001 1 ,0.01
Adj R
2 = variance accounted for by estimated years to diagnosis of Huntington’s disease (HD) after accounting for covariates (see
statistical methods section) and degrees of freedom used for non-linear fit.
HVLT, Hopkins Verbal Learning Test; Non-linear df, degrees of freedom for non-linear fit; non-linear p value, p value for non-linear
element of estimated years to HD diagnosis fit.
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the relationship that would be seen if true years to diagnosis
were known, it can be shown that an accurate expected time
proxy leads to approximations providing useful bounds on the
true average relationships. For example, the (essentially)
uniformly concave or convex nature of each curve in fig 3
allows invocation of Jensen’s inequality
33 to suggest that we are
estimating an upper limit to the true time course of mean
change. Further mathematical arguments beyond the realm of
this paper also show that it is unlikely that this upper bound
dramatically overestimates the true mean time of onset of these
deficits. Hence while resisting the temptation to over interpret
these curves, we feel comfortable in our claim that they are
strong evidence that detectable deficits begin between 10 and
20 years before HD diagnosis in the average CAG expanded
subject. A more detailed and mathematical exposition regarding
the limits of interpretability for this class of prognostic model
will also be forthcoming in a separate report.
Which of the outcomes described here is the strongest marker
of developing HD? Again, we must remember that the models
we have presented actually reflect the relationship between
these markers and another known marker—CAG repeat length
(corrected for age). While the relative strengths of these
relationships provide a tentative basis for judgment, they are
not guaranteed to reflect the relative prognostic importance
that we will eventually observe with actual clinical diagnosis
times. Similarly, we cannot yet know to what extent each
measure independently contributes prognostic information. For
example, striatal volume shows the strongest relationship to
estimated prognosis in our analyses. Given the well known
central role of basal ganglia deterioration in HD, we will not be
surprised if this measure remains the strongest individual
predictor when we can analyse observed onset. Nonetheless, it
is possible that its relative strength in the current analysis could
be due to an especially tight CAG length association that does
not necessarily translate into the best incremental independent
prediction of true prognosis.
Our findings of cognitive, sensory, motor and striatal
volumetric changes well before disease diagnosis are unequi-
vocal, but it remains unknown whether these changes are of
functional significance until our longitudinal data are acquired.
Also, it is not known whether there are very subtle abnorm-
alities, perhaps imperfectly reflected in these markers, prior to
the evident upper limits that we have estimated here. Although
not included in the current report, the Predict-HD study
includes a comparison group of participants who are from HD
families but are known not to have the CAG expansion. Once
sufficient data from this sample become available, it may be
possible to detect subtle abnormalities even earlier than the
current report suggests.
Current hopes for reducing the burden of neurodegenerative
disease rely on the idea of preventing disease onset and slowing
progression so that people at risk may live out a longer portion
of their lifespan as healthy, fully functioning individuals. For
this to be possible, promising therapeutic agents must be tested
for their ability to slow early disease progression. These cross
sectional findings from Predict-HD indicate the approximate
time scale of measurable disease development, and suggest
disease markers which may be candidate surrogates for use in
preventive trials. Furthermore, even markers that fail as
treatment response surrogates will have great value for risk
stratification in such trials. With validation and refinement
through longitudinal study, it will be possible in just a few more
years to confirm such markers, making it feasible to initiate the
first preventive trials in individuals with the HD CAG
expansion prior to functional decline and diagnosis.
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